A different engineering solution to the same half-life problem. Rather than acylation and albumin binding, dulaglutide covalently fuses two GLP-1 analog molecules to an IgG4 Fc fragment. The resulting protein is far too large for renal clearance and is recycled by the neonatal Fc receptor, giving a weekly dosing interval. Receptor pharmacology is standard GLP-1.
The AWARD programme established glycaemic efficacy in type 2 diabetes, and REWIND reported cardiovascular outcome benefit in a population with a substantial primary-prevention component. A mature, well-evidenced agent.
FDA-approved for type 2 diabetes and cardiovascular risk reduction. Prescription-only. Not approved for weight management, unlike semaglutide and tirzepatide.
Boxed warning for rodent thyroid C-cell tumours; MTC/MEN2 contraindication. Gastrointestinal effects. Physician supervision required.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.